Literature DB >> 12972938

Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir.

Seth M Pransky1, James T Albright, Anthony E Magit.   

Abstract

OBJECTIVE: Cidofovir is an acyclic nucleotide phosphonate antiviral medication that has been used intralesionally for the treatment of severe respiratory papillomatosis (RRP) in pediatric patients. The long-term efficacy of this medication was assessed in 11 children with severe RRP who previously required operative debulking every 2 to 6 weeks to maintain airway patency. STUDY
DESIGN: Clinical case series.
RESULTS: Ten of these children have completed therapy. Five are disease free over a mean follow-up period of 51.6 months. Five other patients with active RRP decreased their mean severity scores from 17.8 (range 11-26) to 4.0 (range 2-6) and no longer require cidofovir. One patient continues to receive cidofovir for recurrent disease after an initial favorable response. Throughout the 6-year observational period, no patients demonstrated any adverse effects, laboratory abnormalities, or evidence of carcinogenesis.
CONCLUSION: Intralesional cidofovir is a useful adjunct for managing children with tenuous airways caused by previously uncontrolled papilloma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972938     DOI: 10.1097/00005537-200309000-00032

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  15 in total

1.  Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir--a prospective study.

Authors:  Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-22       Impact factor: 2.503

2.  Intralesional Cidofovir application in recurrent laryngeal papillomatosis.

Authors:  Annett Pudszuhn; Cornelia Welzel; Marc Bloching; Kerstin Neumann
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-10-13       Impact factor: 2.503

Review 3.  [Current therapeutic options for recurrent respiratory papillomatosis].

Authors:  K Huber; H Sadick; K Götte
Journal:  HNO       Date:  2005-11       Impact factor: 1.284

4.  Recurrent respiratory papillomatosis causing chronic stridor and delayed speech in an 18-month-old boy.

Authors:  Adel Alharbi; Derek Drummond; Alfredo Pinto; Valerie Kirk
Journal:  Can Respir J       Date:  2006-10       Impact factor: 2.409

5.  Use of reprogrammed cells to identify therapy for respiratory papillomatosis.

Authors:  Hang Yuan; Scott Myers; Jingang Wang; Dan Zhou; Jennifer A Woo; Bhaskar Kallakury; Andrew Ju; Michael Bazylewicz; Yvonne M Carter; Christopher Albanese; Nazaneen Grant; Aziza Shad; Anatoly Dritschilo; Xuefeng Liu; Richard Schlegel
Journal:  N Engl J Med       Date:  2012-09-27       Impact factor: 91.245

Review 6.  Recurrent respiratory papillomatosis.

Authors:  R A Tasca; R W Clarke
Journal:  Arch Dis Child       Date:  2006-08       Impact factor: 3.791

7.  Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: an international retrospective study on 635 RRP patients.

Authors:  R E A Tjon Pian Gi; T Ilmarinen; E R van den Heuvel; L M Aaltonen; J Andersen; J W Brunings; M Chirila; A Dietz; F Ferran Vilà; G Friedrich; H H W de Gier; W Golusinski; M Graupp; A Hantzakos; R Horcasitas; J Jackowska; J C Koelmel; G Lawson; F Lindner; M Remacle; C Sittel; V Weichbold; M Wierzbicka; F G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-03       Impact factor: 2.503

Review 8.  [Laryngeal papillomatosis: etiology, diagnostics and therapy].

Authors:  M Andratschke; C Betz; A Leunig
Journal:  HNO       Date:  2008-12       Impact factor: 1.284

Review 9.  Recurrent respiratory papillomatosis.

Authors:  Naren N Venkatesan; Harold S Pine; Michael P Underbrink
Journal:  Otolaryngol Clin North Am       Date:  2012-06       Impact factor: 3.346

10.  Treatment of recurrent respiratory papillomatosis and adverse reactions following off-label use of cidofovir (Vistide®).

Authors:  Robin E A Tjon Pian Gi; Andreas Dietz; Vojko Djukic; Hans E Eckel; Gerhard Friedrich; Wojciech Golusinski; Anastasios Hantzakos; George Lawson; Marc Remacle; Heikki Rihkanen; Frederik G Dikkers
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-10-22       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.